Lilly's Elanco unit expects IPO to raise up to $1.45 billion
Reuters
Published Sep 06, 2018 07:39AM ET
Lilly's Elanco unit expects IPO to raise up to $1.45 billion
(Reuters) - Eli Lilly & Co's Elanco Animal Health unit on Thursday said it expects its initial public offering of 62.9 million shares to raise up to $1.45 billion.
The IPO is expected to be priced between $20-$23 per share. At the high end of the range, the company would have a valuation of about $8 billion.
In July, Lilly said it would take Elanco public, marking the end of a nine-month review that weighed options for the unit.
Analysts have cited the strong growth of top animal-health company Zoetis Inc (NYSE:ZTS) since Pfizer (NYSE:PFE) listed it about five years ago.
Zoetis' IPO https://www.reuters.com/article/us-zoetis-idUSBRE90U1EE20130131 raised $2.2 billion and the company currently has a market capitalization of $43 billion.
For the six months ended June 30, Elanco's net income was$9.9 million and the company brought in revenue of $1.5 billion.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.